Haemonetics Corporation (HAE)
Profitability ratios
Return on sales
| Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 26.65% | 26.47% | 51.27% | 46.24% | 49.84% |
| Operating profit margin | 6.35% | 6.72% | 8.19% | 10.43% | 10.63% |
| Pretax margin | 5.85% | 6.09% | 6.45% | 8.47% | 8.97% |
| Net profit margin | 4.53% | 4.97% | 4.40% | 9.24% | 7.87% |
Haemonetics Corporation's profitability ratios have shown some fluctuations over the past five years. The gross profit margin has ranged from 26.47% to 51.27%, with a significant decrease in 2021 followed by a gradual recovery. This may indicate changes in the cost structure or pricing strategy.
The operating profit margin has also varied, declining from 10.63% in 2020 to 6.35% in 2024. This trend suggests that the company's operating expenses relative to sales revenue have increased or its operating income has decreased.
The pretax margin has followed a similar pattern, decreasing from 8.97% in 2020 to 5.85% in 2024. This indicates that the company's pre-tax profitability has been on a downward trend over the past five years.
The net profit margin has shown fluctuations, with a notable dip in 2022 before recovering slightly in 2024. This suggests that the company's overall profitability has been impacted by factors such as taxes, interest expenses, and other non-operating costs.
Overall, these profitability ratios indicate that Haemonetics Corporation has experienced some challenges in maintaining its profitability levels in recent years, possibly due to changes in costs, competitive pressures, or other external factors. Efficient cost management and revenue growth strategies may be needed to improve the company's profitability in the future.
Return on investment
| Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 7.51% | 8.06% | 4.34% | 4.93% | 8.16% |
| Return on assets (ROA) | 5.35% | 5.96% | 2.33% | 4.37% | 6.04% |
| Return on total capital | 9.38% | 9.93% | 6.17% | 6.31% | 11.58% |
| Return on equity (ROE) | 12.25% | 14.11% | 5.79% | 10.86% | 13.03% |
Haemonetics Corporation's profitability ratios show fluctuations over the past five years.
1. Operating return on assets (Operating ROA) decreased from 8.16% in 2020 to 4.34% in 2022 before recovering slightly to 7.51% in 2024. This ratio indicates the efficiency of the company in generating operating income from its total assets, with the recent increase showing improved operational performance.
2. Return on assets (ROA) also fluctuated, ranging from 6.04% in 2020 to 2.33% in 2022, before increasing to 5.35% in 2024. ROA reflects the company's overall ability to generate profits from its assets, with the latest figure indicating a moderate improvement.
3. Return on total capital shows a similar trend, with a decrease from 11.58% in 2020 to 6.17% in 2022 before rising to 9.38% in 2024. This ratio evaluates how efficiently the company generates returns from both debt and equity capital invested.
4. Return on equity (ROE) fluctuated as well, ranging from 13.03% in 2020 to 5.79% in 2022, before increasing to 12.25% in 2024. ROE measures the company's ability to generate profits from shareholders' equity, with the recent improvement indicating a better return for equity investors.
In summary, Haemonetics Corporation has exhibited varying levels of profitability over the past five years, with recent improvements in profitability ratios suggesting a positive trend in the company's performance. However, continuous monitoring is essential to assess the sustainability of these improvements and ensure long-term profitability.